Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 3068

1.

Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.

Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T.

Pharmacoepidemiol Drug Saf. 2016 May 27. doi: 10.1002/pds.4034. [Epub ahead of print]

PMID:
27229855
2.

In response to "Conservative Management of Intentional Massive Dabigatran Overdose".

Cantrell FL.

J Am Geriatr Soc. 2016 May;64(5):1147. doi: 10.1111/jgs.14120. No abstract available.

PMID:
27225374
3.

Idarucizumab for dabigatran overdose.

Peetermans M, Pollack C Jr, Reilly P, Liesenborghs L, Jacquemin M, Levy JH, Weitz JI, Verhamme P.

Clin Toxicol (Phila). 2016 May 25:1-3. [Epub ahead of print]

PMID:
27224445
4.

Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.

Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ.

BMJ. 2016 May 24;353:i2607. doi: 10.1136/bmj.i2607.

5.

Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.

Schuh T, Reichardt B, Finsterer J, Stöllberger C.

J Thromb Thrombolysis. 2016 May 24. [Epub ahead of print]

PMID:
27221106
6.

Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.

Minhas AS, Jiang Q, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD.

J Thromb Thrombolysis. 2016 May 23. [Epub ahead of print]

PMID:
27217043
7.

An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma.

Amiral J, Dunois C, Amiral C, Seghatchian J.

Transfus Apher Sci. 2016 May 16. pii: S1473-0502(16)30040-4. doi: 10.1016/j.transci.2016.05.016. [Epub ahead of print] Review.

PMID:
27216543
8.

Reversal of newer direct oral anticoagulant drugs (DOACs).

Hussain SS, Tyroch AH, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2016 May 24. [Epub ahead of print]

PMID:
27215215
9.

News on implementing two new patient-focused strategies: A patient blood management program in Norway and validation of two dedicated assays for measuring Dabigatran when used for long term antithrombotic therapy.

Seghatchian J.

Transfus Apher Sci. 2016 May 13. pii: S1473-0502(16)30033-7. doi: 10.1016/j.transci.2016.05.014. [Epub ahead of print] Review. No abstract available.

PMID:
27211043
10.

Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.

Samama CM, Rosencher N, Kleine E, Feuring M, Brueckmann M, Clemens A, Gullberg J, Frostick SP.

Thromb Res. 2016 May 14;143:103-110. doi: 10.1016/j.thromres.2016.05.014. [Epub ahead of print]

PMID:
27208980
11.

Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.

Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS.

J Am Heart Assoc. 2016 May 20;5(5). pii: e003206. doi: 10.1161/JAHA.116.003206.

12.

Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.

Stabile E, Izzo R, Rozza F, Losi MA, Coscioni E, Trimarco B.

High Blood Press Cardiovasc Prev. 2016 May 20. [Epub ahead of print]

PMID:
27207360
13.

Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease.

Kooiman J, van der Hulle T, Maas H, Wiebe S, Formella S, Clemens A, van Buren M, Janssen M, Rabelink TJ, Huisman MV.

J Am Coll Cardiol. 2016 May 24;67(20):2442-4. doi: 10.1016/j.jacc.2016.03.516. No abstract available.

PMID:
27199067
14.
15.
16.

Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.

Ren W, Ren Y, Wang S.

Eur J Med Chem. 2016 May 10;120:148-159. doi: 10.1016/j.ejmech.2016.05.020. [Epub ahead of print]

PMID:
27187866
17.

Dabigatran etexilate reduces thrombin-induced inflammation and thrombus formation in experimental ischemic stroke.

Dittmeier M, Wassmuth K, Schuhmann MK, Kraft P, Kleinschnitz C, Fluri F.

Curr Neurovasc Res. 2016 May 17. [Epub ahead of print]

PMID:
27184031
18.

Idarucizumab for Dabigatran Reversal Guideline.

Reardon DP, Owusu K.

Crit Pathw Cardiol. 2016 Jun;15(2):33-5. doi: 10.1097/HPC.0000000000000074. No abstract available.

PMID:
27183250
19.

Non-vitamin K antagonist oral anticoagulant reversal: hope is on the horizon.

Yorkgitis BK.

Am J Surg. 2016 Apr 13. pii: S0002-9610(16)30154-4. doi: 10.1016/j.amjsurg.2016.01.029. [Epub ahead of print] Review.

PMID:
27182049
20.

Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.

Martin K, Moll S.

Thromb Res. 2016 Apr 26;143:40-44. doi: 10.1016/j.thromres.2016.04.019. [Epub ahead of print]

PMID:
27179131
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk